Draft:Michelle Rozo
 | Review waiting, please be patient.
This may take 8 weeks or more, since drafts are reviewed in no specific order. There are 1,816 pending submissions waiting for review.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Reviewer tools
|
| Submission declined on 17 December 2024 by Significa liberdade (talk). This submission appears to be taken from https://insights.crdfglobal.org/breaking-barriers-2024. Wikipedia cannot accept material copied from elsewhere, unless it explicitly and verifiably has been released to the world under a suitably free and compatible copyright license or into the public domain and is written in an acceptable tone—this includes material that you own the copyright to. You should attribute the content of a draft to outside sources, using citations, but copying and pasting or closely paraphrasing sources is not acceptable. The entire draft should be written using your own words and structure.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
This draft has been resubmitted and is currently awaiting re-review. |  |
This submission has now been cleaned of the above-noted copyright violation and its history redacted by an administrator to remove the infringement. If re-submitted (and subsequent additions do not reintroduce copyright problems), the content may be assessed on other grounds.
Dr. Michelle Rozo is an American molecular biologist and biotechnology policy expert. She has held numerous government positions and currently serves as the Vice Chair of the National Security Commission on Emerging Biotechnology.[1]
Early life
[edit]Dr. Rozo received a Bachelor of Arts in biology from Northwestern University.[2] She received a Doctor of Philosophy in biology from Johns Hopkins University's Cell, Molecular, Developmental Biology and Biophysics Program.[3]
Career
[edit]After completing her PhD, Dr. Rozo worked in various government roles, including a civilian job with the U.S. Navy as well as positions in the U.S. Senate and the U.S. State Department.[4]
After joining the Department of Defense as a Senior Advisor in 2019, in 2020 Dr. Rozo became the Department of Defense's Principal Director for Biotechnology in the Office of the Undersecretary of Defense for Research and Engineering.[5][6]
From February 2021 to December 2022, Dr. Rozo was Director of Technology and National Security at the U.S. National Security Council.[3][7]
In December 2022, Senator Chuck Schumer appointed Dr. Rozo to the National Security Commission on Emerging Biotechnology.[1] In her role as Vice Chair of the Commission, Dr. Rozo has presented at international conferences and represented the Commission publicly to speak about the intersection of emerging biotechnology and national security, particularly regarding biotechnology's convergence with artificial intelligence and U.S. strategic competition with the People's Republic of China.[8][9][10] Dr. Rozo has testified before multiple Congressional and government committees.[11] [12]
Prior to delivering the Commission's major report to Congress, Dr. Rozo stated the following in relation to her views on the U.S. government's role in promoting and protecting biotechnology:
- "It’s clear that the pharmaceutical applications will continue to be developed, because there is a market for high-performance drugs. We’re seeing more and more types of drugs enter the market all the time. We have new weight-loss drugs like Ozempic which target the GLP-1 receptor. These drugs have the ability to not reach just a specific defined clinical population — say, someone that’s suffering from heart disease or cancer — but actually large percentages of our population. We’ll see more and more of those types of drugs that have larger and larger market sizes. The market will always, I think, continue to bear out some of those advances. In my view, the other applications of advanced biotech[nology] will struggle without additional government support or allocation of strategic resources."[13]
- “Genomic data will provide the blueprint for future biotech products and capabilities to grow the economy, but in the wrong hands, it could also be weaponized to create engineered pathogens or misused to identify and target individuals. Genomic data is a strategic resource, and the United States needs to treat it as such.”[14]
- “One of the risks that we’re examining at the commission is the risk that we don’t reach this inflection point at the convergence of AI and biotech before an adversary does, particularly an adversary that has different ethics, different beliefs than we do.”[15]
In 2023, Dr. Rozo joined In-Q-Tel as a Vice President of Technology.[16]
External Links
[edit]- Official biography
- "The Promise of Engineering Biology for Sustaining U.S. Leadership in Agriculture"
References
[edit]- ^ a b "Armed Services Committees Leadership Announces Chair and Vice Chair Selections for National Security Commission on Emerging Biotechnology". House Armed Services Committee - Democrats. 2022-12-30. Retrieved 2024-12-17.
- ^ "Career Talk: A Path to Science Policy | Graduate Student Resource Center (GradPost)". gradpost.ucsb.edu. Retrieved 2024-12-17.
- ^ a b "Breaking Barriers 2024". insights.crdfglobal.org. Retrieved 2024-12-17.
- ^ Titus, Alexander (2020-08-18). "From Ebola in Africa to biotechnology in Washington DC — with Michelle Rozo". Bioeconomy.XYZ. Retrieved 2024-12-17.
- ^ "Dr Michelle Rozo". www.ndia.org. Retrieved 2024-12-17.
- ^ www.nationaldefensemagazine.org https://www.nationaldefensemagazine.org/articles/2020/7/24/military-to-leverage-new-biotech-fields-to-gain-an-edge. Retrieved 2024-12-17.
{{cite web}}: Missing or empty|title=(help) - ^ "NAWCWD, Amyris collaborate to develop, test high-energy biosynthetic fuel | NAVAIR". www.navair.navy.mil. Retrieved 2024-12-17.
- ^ "U.S.-China Economic and Security Review Commission hearing on "Current and Emerging Technologies in U.S.-China Economic and National Security Competition" Prepared statement by Michelle Rozo, Vice Chair National Security Commission on Emerging Biotechnology" (PDF). February 1, 2024. Retrieved December 17, 2024.
- ^ "COVID-19". The Pandora Report. 2024-12-06. Retrieved 2024-12-17.
- ^ "Genenta's CEO to present at the U.S. Senate meeting on "Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective"". October 23, 2024.
- ^ "Hearing: Current and Emerging Technologies in U.S.-China Competition". www.uscc.gov. Retrieved 2024-12-17.
- ^ "ISAB Report on Biotechnology in the People's Republic of China's Military-Civil Fusion Strategy" (PDF). October 2024.
- ^ Schneider, Jordan. "Biotech 201". www.chinatalk.media. Retrieved 2024-12-17.
- ^ "New Biden order would stem flow of Americans' sensitive data to China". The Washington Post. February 26, 2024.
- ^ Schumaker, Erin; Reader, Ruth; Payne, Daniel; Paun, Carmen (2024-02-09). "To measure loneliness, start here". POLITICO. Retrieved 2024-12-17.
- ^ "2023 Speakers". Vanderbilt University. Retrieved 2024-12-17.